DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Yuna Rapoport - 1 — you’ll - 1 ” - 1 Rapoport - 1 “ - 1 — - 1 Thierry Hufnagel - 1 Gucci - 1
Top related locs:
Manhattan generics Norwich
Top related orgs:
NBC - 1 Eyecare - 1 Burberry - 1 Carrera - 1 Nike - 1 Eyebuydirect - 1 Armani Exchange - 1 ” - 1

Search resuls for: "Eyecare"


4 mentions found


☆ Where to buy glasses online, according to editors and experts
  + stars: | 2024-09-19 | by ( Bethany Heitman | Bethany Heitman Is A Contributing Editor At Nbc Select. | ) www.nbcnews.com   time to read: +11 min
SKIP AHEAD How we picked the best online eyeglasses retailers | Where to buy glasses online | Why trust NBC Select? To help guide you through buying glasses online we asked experts what to consider before shopping, and we rounded up some of the best online retailers for eyeglasses. Where to buy glasses onlineWe rounded up some of the most popular online eyeglasses retailers to make your online search for glasses easier. Those nervous about shopping online may find comfort in buying glasses from a known name in the glasses world. For this story, she interviewed two experts on where to buy glasses online.
Persons: Yuna Rapoport, — you’ll, ”, Rapoport, “, —, Thierry Hufnagel, Gucci, Kate Spade, Marc Jacobs, Ban, you’ve, Tom Ford, Versace, Prada, Persol, you’ll, Bethany Heitman, TikTok Organizations: NBC, Eyecare, Burberry, Carrera, Nike, Eyebuydirect, Armani Exchange, ”, Facebook, Twitter Locations: Manhattan
☆ Bausch Health investors are left in a holding pattern as 2 major overhangs remain unresolved
  + stars: | 2024-05-02 | by ( Jim Cramer | ) www.cnbc.com   time to read: +5 min
Bausch Health Companies on Tuesday morning reported first-quarter top- and bottom-line misses — putting embattled shares under pressure. BHC YTD mountain Bausch Health YTD Bottom line Along with quarterly results, Bausch Health reaffirmed forward guidance. While not necessarily expected to see a massive increase in adoption in the future like Lilly's GLP-1s, Xifaxan currently accounts for 41% of Bausch Health sales, excluding B+L. Breaking that down: $4.7 billion to $4.85 billion are attributable to Bausch Health (implying 2% to 5% organic growth), with $4.6 billion to $4.7 billion attributable to Bausch + Lomb. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons: Bausch, Eli Lilly, It's, Xifaxan, Jim Cramer's, Jim Cramer, Jim, Rafael Henrique Organizations: Health, Bausch Health, Norwich Pharmaceuticals, Amneal Pharmaceuticals, Food and Drug Administration, Management, CNBC Locations: generics, Norwich
☆ Here are Wednesday's biggest analyst calls: Apple, Tesla, Walmart, Chevron, Lumentum, Rivian & more
  + stars: | 2023-05-10 | by ( Michael Bloom | ) www.cnbc.com   time to read: +7 min
Barclays initiates 10X Genomics as overweight Barclays said in its initiation of the gene sequencing biotech company that it has margin expansion opportunities for 10X. Barclays reiterates Apple as equal weight Barclays said in its analysis of Apple TV+ that "incremental content spend could take some cash away from buybacks." Goldman Sachs reiterates Chevron as neutral Goldman said it's waiting for an "upstream inflection" before getting positive on Chevron shares. Bank of America reiterates Virgin Galactic as underperform Bank of America said it still sees too much uncertainty for the spaceflight company. Bank of America reiterates Rivian as buy Bank of America saidit's standing by shares of the electric vehicle company after its earnings report on Tuesday.
☆ Bausch Health's stock soars on solid quarterly results, but we have concerns about the recovery
  + stars: | 2023-02-23 | by ( Zev Fima | ) www.cnbc.com   time to read: +4 min
Bottom line The Canadian specialty pharmaceuticals company reported solid results for the fourth quarter, along with favorable forward guidance. Bausch management on Thursday did not offer additional information, other than to reiterate its confidence in the strength of the company's patents. Bausch Health previously started the separation process via an initial public offering of Bausch + Lomb in May 2022. Results at the diversified products division — which includes neurology pharmaceutical products, generics and dentistry products — were hampered by generic competition. Notably, as Bausch Health owns most of Bausch + Lomb, the latter's financials still appear on Thursday's results.
0 next >>
Total: 4